BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21399865)

  • 1. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR.
    Htwe SS; Maeda M; Matsumoto R; Sakamoto N; Murakami S; Yamamoto S; Katoh M; Kumagai N; Hayashi H; Nishimura Y; Ohkura M; Wada H; Taniwaki M; Sugihara T; Otsuki T
    Int J Mol Med; 2011 Jun; 27(6):789-94. PubMed ID: 21399865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
    Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
    J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.
    Inagaki A; Tajima E; Uranishi M; Totani H; Asao Y; Ogura H; Masaki A; Yoshida T; Mori F; Ito A; Yano H; Ri M; Kayukawa S; Kataoka T; Kusumoto S; Ishida T; Hayami Y; Hanamura I; Komatsu H; Inagaki H; Matsuda Y; Ueda R; Iida S
    Leuk Res; 2013 Dec; 37(12):1648-55. PubMed ID: 24210217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
    Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
    Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
    Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
    Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.
    Martin LD; Harizanova J; Zhu G; Righolt CH; Belch AR; Mai S; Pilarski LM
    Genes Chromosomes Cancer; 2012 Aug; 51(8):727-42. PubMed ID: 22489023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
    Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
    Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.
    Specht K; Kremer M; Müller U; Dirnhofer S; Rosemann M; Höfler H; Quintanilla-Martinez L; Fend F
    Clin Cancer Res; 2002 Sep; 8(9):2902-11. PubMed ID: 12231535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
    Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
    Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
    Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
    Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
    Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
    Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma.
    Tajima E; Uranishi M; Iida S; Komatsu H; Nitta M; Ueda R
    Haematologica; 2005 Apr; 90(4):559-62. PubMed ID: 15820958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
    Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
    Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.
    Malgeri U; Baldini L; Perfetti V; Fabris S; Vignarelli MC; Colombo G; Lotti V; Compasso S; Bogni S; Lombardi L; Maiolo AT; Neri A
    Cancer Res; 2000 Aug; 60(15):4058-61. PubMed ID: 10945609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
    Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
    Pruneri G; Fabris S; Baldini L; Carboni N; Zagano S; Colombi MA; Ciceri G; Lombardi L; Rocchi M; Buffa R; Maiolo AT; Neri A
    Am J Pathol; 2000 May; 156(5):1505-13. PubMed ID: 10793062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
    Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
    Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.
    Vinatzer U; Gollinger M; Müllauer L; Raderer M; Chott A; Streubel B
    Clin Cancer Res; 2008 Oct; 14(20):6426-31. PubMed ID: 18927281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
    Akervall J; Borg A; Dictor M; Jin C; Jin Y; Tanner M; Isola J; Mertens F; Wennerberg J
    Int J Oncol; 2002 Jan; 20(1):45-52. PubMed ID: 11743641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.